MIM
EPZM

Monashee Investment Management’s Epizyme, Inc EPZM Stock Holding History

Monashee Investment Management’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-150,000
Closed -$1.86M – 209
2019
Q1 		$1.86M Buy
+150,000
New +$1.68M 0.43% 65
2017
Q3 		– Hold
0
– – – 39
2015
Q2 		– Sell
-59,100
Closed -$1.11M – 105
2015
Q1 		$1.11M Buy
+59,100
New +$1.22M 0.69% 45

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Monashee Investment Management's EPZM Position: Q2 2019 in Review

Monashee Investment Management sold out of Epizyme, Inc (EPZM) in Q2 2019, closing a stake of 150,000 shares — an estimated $1.86M sold.

Monashee Investment Management first reported a position in EPZM in Q1 2015 and held it in 2 quarters. The position peaked at $1.86M in Q1 2019. 134 funds tracked by Wall St. Rank hold EPZM as of Q2 2019.

  • Monashee Investment Management reported no remaining Epizyme, Inc position as of Q2 2019 after selling out during the quarter.
  • Monashee Investment Management sold 150,000 Epizyme, Inc shares in Q2 2019, an estimated $1.86M.
  • Monashee Investment Management first reported a position in Epizyme, Inc in Q1 2015 and held it in 2 quarters.
  • Monashee Investment Management's Epizyme, Inc position peaked at $1.86M in Q1 2019.
  • 134 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2019.

Based on Monashee Investment Management's 13F filing for Q2 2019, filed 7 Aug 2019.